Pipeline

We are developing a pipeline of purpose-built, targeted medicines against genomic drivers of cancer. By designing highly selective medicines, we have the potential to deliver treatments that increase clinical benefit in genomically defined patient populations and fulfill the promise of precision medicine for appropriate patients.